Evidence map›Paper›PMID 28432650›Full record

Trial reportPathology oncology research : POR2018

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Tamás Schneider, András Rosta, Hajna Losonczy, Gáspár Radványi, György Ujj, Miklós Egyed, Árpád Illés, János Jakucs, László Szerafin, Zoltán Gasztonyi and 6 more

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Tamás SchneiderNational Institute of Oncology, Department of Medical Oncology "A" and Hematology, Lymphoma Center, Ráth György u. 7-9, Budapest, 1122, Hungary. schneidertamas@freemail.hu.
András RostaNational Institute of Oncology, Department of Medical Oncology "A" and Hematology, Lymphoma Center, Ráth György u. 7-9, Budapest, 1122, Hungary.
Hajna LosonczyI. Department of Internal Medicine, University of Pécs, Ifjúság út 13, Pécs, 7624, Hungary.
Gáspár RadványiII. Department of Internal Medicine, Semmelweis Hospital, Csabai kapu 9-11, Miskolc, 3529, Hungary.
György UjjI. Department of Internal Medicine, Jász-Nagykun-Szolnok County Hetényi Géza Hospital, Tószegi út 21, Szolnok, 5000, Hungary.
Miklós EgyedDepartment of Internal Medicine and Hematology, Kaposi Mór Hospital, Tallián Gyula u. 20-34, Kaposvár, 7400, Hungary.
Árpád IllésFaculty of Medicine, Department of Hematology, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
János JakucsI. Department of Internal Medicine, Békés County Pándy Kálmán Hospital, Semmelweis u. 1, Gyula, 5700, Hungary.
László SzerafinDepartment of Haematology, Szabolcs-Szatmár-Bereg County Jósa András Hospital, Szent István u. 68, Nyíregyháza, 4400, Hungary.
Zoltán GasztonyiII. Department of Internal Medicine and Hematology, Petz Aladár County Hospital, Vasvári Pál u. 2-4, Győr, 9024, Hungary.
Tamás MassziDepartment of Hematology, Szent István and Szent László Hospital, Nagyvárad tér 1, Budapest, 1097, Hungary.
János IványiDepartment of Hematology, Vas County Markusovszky Hospital, Markusovszky L. u. 5, Szombathely, 9700, Hungary.
Judit DemeterI. Department of Internal Medicine, Semmelweis University, Korányi Sándor u. 2/A, Budapest, 1083, Hungary.
Péter DombiDepartment of Hematology, Szent Borbála Hospital, Dózsa György út 77, Tatabánya, 2800, Hungary.
Antal TóthIV. Department of Internal Medicine, Tolna County Balassa János Hospital, Béri Balogh Ádám u. 5-7, Szekszárd, 7100, Hungary.
Zita BorbényiII. Department of Internal Medicine, University of Szeged, Korányi Fasor 6, Szeged, 6720, Hungary.
Semmelweis University · HUNational Institute of Oncology · HUBékés Megyei Központi Kórház · HUJósa András Múzeum · HUMarkusovszky Egyetemi Oktatókórház · HUPetz Aladár Megyei Oktató Kórház · HUSomogy Megyei Kaposi Mór Oktató Kórház · HUSzent Borbála Kórház · HUSzent János Kórház · HUUniversity of Debrecen · HUUniversity of Pecs · HUUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansInduction ChemotherapyKaplan-Meier EstimateLymphoma, FollicularMaintenance ChemotherapyMaleMiddle AgedRituximabTreatment OutcomeAntineoplastic Agents, ImmunologicalRituximabDrug safetyEvent-free survivalFollicular lymphomaMaintenanceRituximab

Identifiers

PMID28432650
OpenAlexW2605882989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.